[fcb5af]: / literature / by_gene / CCND3.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 34472720 10.1002/cnr2.1545 2022 Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. CCND3
2 34596253 10.1002/hon.2930 2022 Chronic lymphocytic leukemia with t(6;14) (p21;q32) CCND3-IGH: CCND3 rearrangement does not necessarily define a cyclin D1-negative mantle cell lymphoma. CCND3
3 34605949 10.1007/s00277-021-04671-0 2022 Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma. CCND3
4 34617271 10.1111/bjh.17874 2022 Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. CCND3
5 35359039 10.3760/cma.j.cn112151-20210904-00647 2022 [Clinicopathological and molecular genetic features of cyclin D1-negative mantle cell lymphoma]. CCND3
6 35687490 10.1182/bloodadvances.2021006654 2022 Genomic characterization of lymphomas in patients with inborn errors of immunity. CCND3
7 35794096 10.1038/s41467-022-31355-8 2022 Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. CCND3
8 35982976 10.3389/fonc.2022.934008 2022 Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. CCND3
9 33122824 10.1038/s41388-020-01532-4 2021 Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. CCND3
10 33332554 10.1084/jem.20201699 2021 Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. CCND3
11 33399078 10.1016/j.esmoop.2020.100012 2021 Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. CCND3
12 33747936 10.3389/fonc.2021.622648 2021 Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. CCND3
13 33969276 10.1097/HS9.0000000000000563 2021 Acquisition of <i>TCF3</i> and <i>CCND3</i> Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. CCND3
14 34058070 10.1002/1878-0261.13033 2021 NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. CCND3
15 34098582 10.1182/blood.2020007591 2021 MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. CCND3
16 34114641 10.14670/HH-18-351 2021 The pathologic diagnosis of mantle cell lymphoma. CCND3
17 34627430 10.19746/j.cnki.issn.1009-2137.2021.05.019 2021 [Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma]. CCND3
18 31688139 10.1097/PAS.0000000000001390 2020 Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study. CCND3
19 31773249 10.1007/s00428-019-02704-8 2020 Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. CCND3
20 31849147 10.1111/cas.14286 2020 Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. CCND3
21 32059783 10.1016/j.cell.2020.01.029 2020 Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. CCND3
22 32449435 10.1080/15476286.2020.1772559 2020 Burkitt lymphoma-related <i>TCF3</i> mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding. CCND3
23 32738175 10.1002/hon.2784 2020 Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. CCND3
24 33095873 10.1182/bloodadvances.2019001307 2020 Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. CCND3
25 33207194 10.1016/j.celrep.2020.108403 2020 Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells. CCND3
26 30538135 10.1182/blood-2018-07-862151 2019 <i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphoma. CCND3
27 30733272 10.3324/haematol.2018.207928 2019 Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. CCND3
28 31557894 10.3390/cancers11101427 2019 FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. CCND3
29 29071477 10.1007/s12185-017-2360-8 2018 Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion. CCND3
30 29295643 10.1080/10428194.2017.1413186 2018 The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. CCND3
31 29622548 10.1182/blood-2017-10-813576 2018 Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. CCND3
32 30381403 10.1182/bloodadvances.2018019398 2018 Recurrent <i>CCND3</i> mutations in <i>MLL</i>-rearranged acute myeloid leukemia. CCND3
33 27493231 10.1136/jim-2016-000233 2017 Restoration of microRNA-212 causes a G0/G1 cell cycle arrest and apoptosis in adult T-cell leukemia/lymphoma cells by repressing CCND3 expression. CCND3
34 27668411 10.1002/ijc.30444 2017 Synergy of interleukin 10 and toll-like receptor 9 signalling in B cell proliferation: Implications for lymphoma pathogenesis. CCND3
35 28069605 10.1182/blood-2016-11-751024 2017 Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. CCND3
36 28148900 10.18632/oncotarget.14846 2017 Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. CCND3
37 28151717 10.1158/1078-0432.CCR-15-2869 2017 Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. CCND3
38 28209658 10.3324/haematol.2016.156885 2017 Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols. CCND3
39 28607489 10.1038/nature22797 2017 The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. CCND3
40 28671688 10.1038/ng.3909 2017 The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. CCND3
41 28883003 10.1158/0008-5472.CAN-16-2691 2017 Discovery of Human-Similar Gene Fusions in Canine Cancers. CCND3
42 26522721 10.1038/onc.2015.385 2016 ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway. CCND3
43 26647218 10.1158/1078-0432.CCR-15-2123 2016 Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. CCND3
44 26887776 10.1111/bjh.13925 2016 Genetic differences between paediatric and adult Burkitt lymphomas. CCND3
45 27440511 10.1373/clinchem.2016.255315 2016 Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. CCND3
46 27750045 10.1016/j.ajpath.2016.07.027 2016 B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains. CCND3
47 27888884 10.1016/j.hoc.2016.07.009 2016 Update on Burkitt Lymphoma. CCND3
48 27959929 10.1371/journal.pmed.1002197 2016 Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. CCND3
49 25524659 10.3892/or.2014.3677 2015 Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells. CCND3
50 25529125 10.1016/j.humpath.2014.10.021 2015 Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. CCND3
51 25704763 10.1002/ijc.29494 2015 A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting. CCND3
52 25839159 10.18632/oncotarget.3378 2015 Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. CCND3
53 26173642 10.1002/gcc.22268 2015 The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma. CCND3
54 26485640 10.1016/j.yexcr.2015.10.012 2015 MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis. CCND3
55 24345752 10.1182/blood-2013-10-531509 2014 A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. CCND3
56 24492847 10.1101/cshperspect.a014282 2014 Oncogenic mechanisms in Burkitt lymphoma. CCND3
57 25145835 10.1111/bjh.13079 2014 The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. CCND3
58 23240690 10.1111/bjh.12161 2013 Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis. CCND3
59 23255553 10.1182/blood-2012-08-452284 2013 CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. CCND3
60 23422111 2013 Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma. CCND3
61 23782073 10.1586/ehm.13.27 2013 Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis? CCND3
62 21479697 10.1007/s12032-011-9937-5 2012 The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases. CCND3
63 22514694 10.1371/journal.pone.0034975 2012 3,3'-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. CCND3
64 22885699 10.1038/nature11378 2012 Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. CCND3
65 23079656 10.1016/j.ccr.2012.09.016 2012 Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. CCND3
66 21504716 10.1016/j.cancergencyto.2010.08.016 2011 CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. CCND3
67 21606168 10.3324/haematol.2011.041053 2011 Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells. CCND3
68 21945515 10.1016/j.semcancer.2011.09.007 2011 The complex landscape of genetic alterations in mantle cell lymphoma. CCND3
69 21965782 2011 Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma. CCND3
70 20062012 10.1038/modpathol.2009.173 2010 Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. CCND3
71 20107311 10.4161/cc.9.4.10783 2010 Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. CCND3
72 20193116 10.5732/cjc.009.10552 2010 Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma. CCND3
73 20407034 10.1182/blood-2009-12-258822 2010 Pegylated arginase I: a potential therapeutic approach in T-ALL. CCND3
74 20578819 10.3109/10428194.2010.496014 2010 Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. CCND3
75 20956547 10.1084/jem.20091962 2010 Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. CCND3
76 19001083 10.1182/blood-2008-03-147967 2009 Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. CCND3
77 19639271 10.1007/s12185-009-0382-6 2009 Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients. CCND3
78 19704260 10.1097/PDM.0b013e31818935d2 2009 Improved diagnostic segregation of mantle cell lymphoma by determination of cyclin D1/D3 expression ratio in formalin-fixed tissue. CCND3
79 18382684 10.1371/journal.pone.0001911 2008 p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma. CCND3
80 18391076 10.1182/blood-2007-10-118794 2008 Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. CCND3
81 18685613 10.1038/leu.2008.213 2008 Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. CCND3
82 17300668 10.1111/j.1440-1827.2006.02058.x 2007 Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma. CCND3
83 17416736 10.1182/blood-2006-11-059451 2007 NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. CCND3
84 16122798 10.1016/j.leukres.2005.06.025 2006 Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. CCND3
85 16270038 10.1038/sj.leu.2404008 2006 Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. CCND3
86 16614728 10.1038/sj.jid.5700224 2006 Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. CCND3
87 15389259 10.1038/modpathol.3800276 2005 Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. CCND3
88 15665120 10.1182/blood-2003-07-2558 2005 Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. CCND3
89 15948116 10.1016/j.humpath.2005.03.004 2005 Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. CCND3
90 16084951 10.1016/j.humpath.2005.05.013 2005 Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma. CCND3
91 16123218 10.1182/blood-2005-04-1753 2005 Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. CCND3
92 16218953 10.1111/j.1742-4658.2005.04918.x 2005 Analysis of the contribution of changes in mRNA stability to the changes in steady-state levels of cyclin mRNA in the mammalian cell cycle. CCND3
93 16322284 10.1158/1078-0432.CCR-05-1028 2005 Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. CCND3
94 16334487 10.1080/10428190500215100 2005 Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia. CCND3
95 16620575 2005 [Expression, localization and interrelationship of P27kip1 and cyclin D3 in non-Hodgkin's lymphoma]. CCND3
96 15096562 10.1016/S1525-1578(10)60494-1 2004 CyclinD1/CyclinD3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma. CCND3
97 15098007 10.1038/modpathol.3800100 2004 Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. CCND3
98 15305377 10.1002/ijc.20354 2004 Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. CCND3
99 15496980 10.1038/sj.leu.2403500 2004 Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR. CCND3
100 12592386 10.1038/sj.onc.1206193 2003 Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation. CCND3